Gritstone Announces Presentations during Five Upcoming Investor Conferences and Events

EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December. Conference: B. Riley Fall Best Ideas in Oncology Panel Series – Overcoming Checkpoint Resistance in Solid TumorsDate and Time: Thursday, October 28, 2021 at 11:00 a.m. ET Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer Conference: Stifel 2021 Virtual Healthcare ConferenceDate and Time: Monday, November 15, 2021 at 1:20 p.m. ET Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer Conference: Cowen’s 5th Annual IO Next Virtual SummitDate and Time: Monday, November 15, 2021 at 4:15 p.m. ET Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer Conference: Evercore ISI 4th Annual Health CONx Virtual ConferenceDate and Time: Wednesday, December 1, 2021 at 10:05 a.m. ET Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer Conference: Piper Sandler 33rd Annual Healthcare ConferenceDate and Time: November 30-December 2, 2021Presenter: Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer A live webcast of the presentations will be accessible via the Investors & Media section of the company’s website at https://ir.gritstonebio.com/investors/events. An archived replay will be accessible for 30 days following each event. About Gritstone Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com. Gritstone ContactsMedia:Dan Budwick1AB(973) [email protected]  Investors:Tim McCarthy, CFALifeSci Advisors, [email protected]